161 related articles for article (PubMed ID: 23414585)
1. Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial.
Robertson JF; Ferrero JM; Bourgeois H; Kennecke H; de Boer RH; Jacot W; McGreivy J; Suzuki S; Zhu M; McCaffery I; Loh E; Gansert JL; Kaufman PA
Lancet Oncol; 2013 Mar; 14(3):228-35. PubMed ID: 23414585
[TBL] [Abstract][Full Text] [Related]
2. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.
Howell SJ; Casbard A; Carucci M; Ingarfield K; Butler R; Morgan S; Meissner M; Bale C; Bezecny P; Moon S; Twelves C; Venkitaraman R; Waters S; de Bruin EC; Schiavon G; Foxley A; Jones RH
Lancet Oncol; 2022 Jul; 23(7):851-864. PubMed ID: 35671774
[TBL] [Abstract][Full Text] [Related]
3. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Jones RH; Casbard A; Carucci M; Cox C; Butler R; Alchami F; Madden TA; Bale C; Bezecny P; Joffe J; Moon S; Twelves C; Venkitaraman R; Waters S; Foxley A; Howell SJ
Lancet Oncol; 2020 Mar; 21(3):345-357. PubMed ID: 32035020
[TBL] [Abstract][Full Text] [Related]
4. E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.
Connolly RM; Zhao F; Miller KD; Lee MJ; Piekarz RL; Smith KL; Brown-Glaberman UA; Winn JS; Faller BA; Onitilo AA; Burkard ME; Budd GT; Levine EG; Royce ME; Kaufman PA; Thomas A; Trepel JB; Wolff AC; Sparano JA
J Clin Oncol; 2021 Oct; 39(28):3171-3181. PubMed ID: 34357781
[TBL] [Abstract][Full Text] [Related]
5. The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer.
Beaver JA; Park BH
Future Oncol; 2012 Jun; 8(6):651-7. PubMed ID: 22764762
[TBL] [Abstract][Full Text] [Related]
6. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.
Kindler HL; Richards DA; Garbo LE; Garon EB; Stephenson JJ; Rocha-Lima CM; Safran H; Chan D; Kocs DM; Galimi F; McGreivy J; Bray SL; Hei Y; Feigal EG; Loh E; Fuchs CS
Ann Oncol; 2012 Nov; 23(11):2834-2842. PubMed ID: 22700995
[TBL] [Abstract][Full Text] [Related]
7. Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group.
DuBois SG; Krailo MD; Glade-Bender J; Buxton A; Laack N; Randall RL; Chen HX; Seibel NL; Boron M; Terezakis S; Hill-Kayser C; Hayes A; Reid JM; Teot L; Rakheja D; Womer R; Arndt C; Lessnick SL; Crompton BD; Kolb EA; Daldrup-Link H; Eutsler E; Reed DR; Janeway KA; Gorlick RG
J Clin Oncol; 2023 Apr; 41(11):2098-2107. PubMed ID: 36669140
[TBL] [Abstract][Full Text] [Related]
8. Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials.
Rugo HS; Van Poznak CH; Neven P; Danielewicz I; Lee SC; Campone M; Chik JYK; Vega Alonso E; Naume B; Brain E; Siegel JM; Li R; Uema D; Wagner VJ; Coleman RE
Breast Cancer Res Treat; 2024 Apr; 204(2):249-259. PubMed ID: 38123789
[TBL] [Abstract][Full Text] [Related]
9.
Turner NC; Swift C; Kilburn L; Fribbens C; Beaney M; Garcia-Murillas I; Budzar AU; Robertson JFR; Gradishar W; Piccart M; Schiavon G; Bliss JM; Dowsett M; Johnston SRD; Chia SK
Clin Cancer Res; 2020 Oct; 26(19):5172-5177. PubMed ID: 32546646
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor-Positive Breast Cancer: A Randomized Clinical Trial.
Serrano D; Gandini S; Thomas P; Crew KD; Kumar NB; Vornik LA; Lee JJ; Veronesi P; Viale G; Guerrieri-Gonzaga A; Lazzeroni M; Johansson H; D'Amico M; Guasone F; Spinaci S; Bertelsen BE; Mellgren G; Bedrosian I; Weber D; Castile T; Dimond E; Heckman-Stoddard BM; Szabo E; Brown PH; DeCensi A; Bonanni B
JAMA Oncol; 2023 May; 9(5):664-672. PubMed ID: 36951827
[TBL] [Abstract][Full Text] [Related]
11. Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.
Bachelot T; Cottu P; Chabaud S; Dalenc F; Allouache D; Delaloge S; Jacquin JP; Grenier J; Venat Bouvet L; Jegannathen A; Campone M; Del Piano F; Debled M; Hardy-Bessard AC; Giacchetti S; Mouret-Reynier MA; Barthelemy P; Kaluzinski L; Mailliez A; Legouffe E; Sephton M; Bliss J; Canon JL; Penault-Llorca F; Lemonnier J; Cameron D; Andre F
J Clin Oncol; 2022 Nov; 40(32):3699-3708. PubMed ID: 35605174
[TBL] [Abstract][Full Text] [Related]
12. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer: a long-term safety and overall survival update from the randomised, double-blind, placebo-controlled, phase 3 trial.
Zhang Q; Li W; Hu X; Sun T; Cui S; Wang S; Ouyang Q; Yin Y; Geng C; Tong Z; Cheng Y; Ning Z; Jiang Z
Transl Breast Cancer Res; 2023; 4():18. PubMed ID: 38751475
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial.
Iwata H; Nakamura R; Masuda N; Yamashita T; Yamamoto Y; Kobayashi K; Tsurutani J; Iwasa T; Yonemori K; Tamura K; Aruga T; Tokunaga E; Kaneko K; Lee MJ; Yuno A; Kawabata A; Seike T; Kaneda A; Nishimura Y; Trepel JB; Saji S
Jpn J Clin Oncol; 2023 Jan; 53(1):4-15. PubMed ID: 36398439
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma.
Akshintala S; Sundby RT; Bernstein D; Glod JW; Kaplan RN; Yohe ME; Gross AM; Derdak J; Lei H; Pan A; Dombi E; Palacio-Yance I; Herrera KR; Miettinen MM; Chen HX; Steinberg SM; Helman LJ; Mascarenhas L; Widemann BC; Navid F; Shern JF; Heske CM
Clin Cancer Res; 2023 Sep; 29(17):3329-3339. PubMed ID: 37398992
[TBL] [Abstract][Full Text] [Related]
15. Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.
Yee D; Isaacs C; Wolf DM; Yau C; Haluska P; Giridhar KV; Forero-Torres A; Jo Chien A; Wallace AM; Pusztai L; Albain KS; Ellis ED; Beckwith H; Haley BB; Elias AD; Boughey JC; Kemmer K; Yung RL; Pohlmann PR; Tripathy D; Clark AS; Han HS; Nanda R; Khan QJ; Edmiston KK; Petricoin EF; Stringer-Reasor E; Falkson CI; Majure M; Mukhtar RA; Helsten TL; Moulder SL; Robinson PA; Wulfkuhle JD; Brown-Swigart L; Buxton M; Clennell JL; Paoloni M; Sanil A; Berry S; Asare SM; Wilson A; Hirst GL; Singhrao R; Asare AL; Matthews JB; Hylton NM; DeMichele A; Melisko M; Perlmutter J; Rugo HS; Fraser Symmans W; Van't Veer LJ; Berry DA; Esserman LJ
NPJ Breast Cancer; 2021 Oct; 7(1):131. PubMed ID: 34611148
[TBL] [Abstract][Full Text] [Related]
16. The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32.
Pimentel I; Chen BE; Lohmann AE; Ennis M; Ligibel J; Shepherd L; Hershman DL; Whelan T; Stambolic V; Mayer I; Hobday T; Lemieux J; Thompson A; Rastogi P; Gelmon K; Rea D; Rabaglio M; Ellard S; Mates M; Bedard P; Pitre L; Vandenberg T; Dowling RJO; Parulekar W; Goodwin PJ
J Natl Cancer Inst; 2021 Feb; 113(2):192-198. PubMed ID: 33527137
[TBL] [Abstract][Full Text] [Related]
17. E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer.
Yeruva SLH; Zhao F; Miller KD; Tevaarwerk AJ; Wagner LI; Gray RJ; Sparano JA; Connolly RM
NPJ Breast Cancer; 2018; 4():1. PubMed ID: 29354686
[TBL] [Abstract][Full Text] [Related]
18. Results from the Children's Oncology Group phase III trial of a monoclonal antibody against the insulin-like growth factor-1 receptor in patients with newly diagnosed metastatic Ewing sarcoma.
Carcaboso AM
Transl Pediatr; 2023 Oct; 12(10):1916-1919. PubMed ID: 37969125
[No Abstract] [Full Text] [Related]
19. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.
Johnston SR; Kilburn LS; Ellis P; Dodwell D; Cameron D; Hayward L; Im YH; Braybrooke JP; Brunt AM; Cheung KL; Jyothirmayi R; Robinson A; Wardley AM; Wheatley D; Howell A; Coombes G; Sergenson N; Sin HJ; Folkerd E; Dowsett M; Bliss JM;
Lancet Oncol; 2013 Sep; 14(10):989-98. PubMed ID: 23902874
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
